E
84.24
0.32 (0.38%)
| Previous Close | 83.92 |
| Open | 84.35 |
| Volume | 2,110,005 |
| Avg. Volume (3M) | 4,513,820 |
| Market Cap | 49,457,303,552 |
| Price / Earnings (TTM) | 36.95 |
| Price / Earnings (Forward) | 29.33 |
| Price / Sales | 8.32 |
| Price / Book | 4.74 |
| 52 Weeks Range |
| Profit Margin | 75.71% |
| Operating Margin (TTM) | 29.01% |
| Diluted EPS (TTM) | 2.42 |
| Quarterly Revenue Growth (YOY) | 6.20% |
| Quarterly Earnings Growth (YOY) | 1.70% |
| Total Debt/Equity (MRQ) | 6.86% |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | 876.20 M |
| Levered Free Cash Flow (TTM) | 1.45 B |
| Return on Assets (TTM) | 8.42% |
| Return on Equity (TTM) | 16.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Edwards Lifesciences Corporatio | Bullish | Bullish |
AIStockmoo Score
-0.1
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -1.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -1.5 |
| Average | -0.10 |
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.91% |
| % Held by Institutions | 89.29% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Jennison Associates Llc | 30 Sep 2025 | 13,958,774 |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt | 30 Sep 2025 | 9,240,197 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 104.00 (Goldman Sachs, 23.46%) | Buy |
| Median | 97.00 (15.15%) | |
| Low | 88.00 (Baird, 4.46%) | Hold |
| Average | 96.44 (14.48%) | |
| Total | 11 Buy, 5 Hold | |
| Avg. Price @ Call | 84.56 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 11 Dec 2025 | 101.00 (19.90%) | Buy | 84.24 |
| 31 Oct 2025 | 96.00 (13.96%) | Buy | 82.45 | |
| Barclays | 08 Dec 2025 | 103.00 (22.27%) | Buy | 84.32 |
| 31 Oct 2025 | 99.00 (17.52%) | Buy | 82.45 | |
| BTIG | 05 Dec 2025 | 103.00 (22.27%) | Buy | 86.19 |
| 25 Nov 2025 | 100.00 (18.71%) | Buy | 86.82 | |
| Baird | 05 Dec 2025 | 88.00 (4.46%) | Hold | 86.19 |
| Canaccord Genuity | 05 Dec 2025 | 89.00 (5.65%) | Hold | 86.19 |
| 03 Nov 2025 | 84.00 (-0.28%) | Hold | 83.07 | |
| RBC Capital | 05 Dec 2025 | 100.00 (18.71%) | Buy | 86.19 |
| 31 Oct 2025 | 95.00 (12.77%) | Buy | 82.45 | |
| Stifel | 05 Dec 2025 | 100.00 (18.71%) | Buy | 86.19 |
| 31 Oct 2025 | 95.00 (12.77%) | Buy | 82.45 | |
| Truist Securities | 05 Dec 2025 | 92.00 (9.21%) | Hold | 86.19 |
| 03 Nov 2025 | 90.00 (6.84%) | Hold | 83.07 | |
| UBS | 05 Dec 2025 | 92.00 (9.21%) | Hold | 86.19 |
| Wells Fargo | 05 Dec 2025 | 96.00 (13.96%) | Buy | 86.19 |
| Evercore ISI Group | 31 Oct 2025 | 92.00 (9.21%) | Buy | 82.45 |
| 07 Oct 2025 | 88.00 (4.46%) | Buy | 76.72 | |
| Goldman Sachs | 31 Oct 2025 | 104.00 (23.46%) | Buy | 82.45 |
| JP Morgan | 31 Oct 2025 | 90.00 (6.84%) | Hold | 82.45 |
| Mizuho | 31 Oct 2025 | 100.00 (18.71%) | Buy | 82.45 |
| Piper Sandler | 31 Oct 2025 | 95.00 (12.77%) | Buy | 82.45 |
| Jefferies | 29 Oct 2025 | 98.00 (16.33%) | Buy | 82.69 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MARKOWITZ WAYNE | - | 84.32 | -583 | -49,159 |
| Aggregate Net Quantity | -583 | |||
| Aggregate Net Value ($) | -49,159 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 84.32 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MARKOWITZ WAYNE | Officer | 08 Dec 2025 | Sell (-) | 583 | 84.32 | 49,159 |
| Date | Type | Details |
|---|---|---|
| 04 Dec 2025 | Announcement | Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference |
| 09 Nov 2025 | Announcement | Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease |
| 09 Nov 2025 | Announcement | Driving Timely Diagnosis And Treatment For Heart Valve Disease To Save Lives |
| 30 Oct 2025 | Announcement | Edwards Lifesciences Announces CFO Transition Plan |
| 30 Oct 2025 | Announcement | Edwards Lifesciences Reports Third Quarter Results |
| 27 Oct 2025 | Announcement | Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025 |
| 27 Oct 2025 | Announcement | Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025 |
| 23 Oct 2025 | Announcement | Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |